DENTSPLY SIRONA (XRAY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on June 17. Analyst Michael Cherny from Leerink Partners reiterated a Hold rating on the stock and has a $16.50 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Michael Cherny has given his Hold rating due to a combination of factors surrounding DENTSPLY SIRONA’s current strategic focus and market conditions. The new CFO, Matthew Garth, has emphasized a strong focus on margin expansion, cost management, and internal investments, which are seen as positive steps towards improving financial performance. However, Cherny notes that while these efforts are commendable, there is still a lack of detailed disclosure regarding the new management team’s long-term strategic plans.
Additionally, Cherny expresses concerns about the company’s ability to achieve significant revenue growth in the face of challenging market conditions. Despite the potential for margin improvement, the uncertainty surrounding topline growth prospects and the need for more clarity on future strategies contribute to the Hold rating. As such, while the focus on margins is appreciated, the overall outlook remains cautious until more information is available.
In another report released yesterday, Wells Fargo also maintained a Hold rating on the stock with a $16.00 price target.